Recently Featured

Obesity Drugs May Silence the ‘Drug Noise’ Behind All Addiction

March 18, 2026
Recent advancements in obesity medications, particularly GLP-1 receptor agonists, are reshaping the conversation around addiction treatment. These drugs, originally developed for weight management, are demonstrating potential effects on reducing cravings and altering the brain’s reward pathways, which could lead to significant implications for addiction therapies. The context of this development lies in the growing recognition…

Codexis Signs Agreement to Manufacture 50 g siRNA Using its ECO Synthesis Manufacturing Platform

March 18, 2026
Codexis, Inc. recently announced it has entered into an agreement with an innovator pharmaceutical company to manufacture 50 grams of small interfering RNA (siRNA) using its proprietary ECO Synthesis manufacturing platform to support preclinical development of a therapeutic candidate targeting a cardiovascular indication. Under the terms of the agreement, Codexis will produce siRNA material to…

Sanofi bets on Sino Biopharm’s transplant drug in $1.5bn licensing deal

March 18, 2026
Sanofi has entered into a significant $1.5 billion licensing agreement with Sino Biopharm for the development of rovadicitinib, a JAK/ROCK inhibitor aimed at treating graft-versus-host disease (GVHD). This drug presents a differentiated mechanism of action compared to existing single-target therapies such as Jakavi and Imbruvica, which have dominated the market. The strategic move underscores Sanofi’s…

Ongoing Cases